Oct 2026
Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients treated with intensive therapy.
B. Paiva, L. Burgos, Carmen González et al.
· Leukemia · 0 citations